- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07826819
Consensus on Low-resource Setting Definition: An inteRnational Delphi sTudY (CLARITY-LRS) (CLARITY-LRS)
Study Overview
Status
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Pedja Kovacevic, MD,PhD
- Phone Number: 051342507
- Email: peko051@yahoo.com
Study Locations
-
-
The Repblic of Srpska
-
Banja Luka, The Repblic of Srpska, Bosnia and Herzegovina, 78000
- University Clinical Centre of the Republic of Srpska
-
Contact:
- Pedja Kovacevic
- Phone Number: 051342507
- Email: peko051@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Adults aged 18 years or older. Healthcare professionals, researchers, policymakers, health system experts, patient representatives, or other stakeholders with relevant knowledge or experience related to healthcare delivery, critical care, global health, health systems, or resource-limited healthcare environments.
Ability to read and understand English. Willingness to provide informed consent and participate in the Delphi process. Access to the internet and ability to complete electronic questionnaires. -
Exclusion Criteria:
Individuals younger than 18 years. Individuals without relevant professional, research, policy, health-system, or lived experience related to the study topic.
Inability to understand the study information or complete the questionnaires in English.
Refusal or inability to provide informed consent. Failure to complete the initial Delphi questionnaire round.
-
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number and proportion of candidate statements rated 7-9 on the 9-point Likert scale
Time Frame: From the first Delphi round through completion of the final Delphi round, up to 12 months
|
International Delphi panelists will rate each candidate statement on a 9-point Likert scale, where 1 indicates strong disagreement and 9 indicates strong agreement.
Consensus for inclusion in the low-resource setting definition will be defined as at least 80% of respondents rating a statement from 7 to 9. The outcome will be summarized as the number and percentage of candidate statements meeting this prespecified consensus threshold after completion of the Delphi process.
|
From the first Delphi round through completion of the final Delphi round, up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number and proportion of candidate statements with stable ratings between consecutive Delphi rounds
Time Frame: From completion of the first Delphi round through completion of the final Delphi round, up to 12 months
|
Stability of ratings will be assessed among panelists who participate in consecutive Delphi rounds.
Ratings assigned using the 9-point Likert scale will be compared between consecutive rounds using the Wilcoxon signed-rank test.
The outcome will be reported as the number and proportion of candidate statements for which no statistically significant change in ratings is observed between consecutive rounds.
|
From completion of the first Delphi round through completion of the final Delphi round, up to 12 months
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 01-19-420-2/26
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.